Aurobindo's Quality Control for Clonazepam Strength
Aurobindo Pharma verifies clonazepam tablet strength through standardized pharmaceutical testing compliant with United States Pharmacopeia (USP) monograph <621> for chromatography and FDA Good Manufacturing Practices (cGMP). This involves high-performance liquid chromatography (HPLC) to quantify the active ingredient against reference standards, ensuring content falls within 90-110% of labeled potency.[1][2]
Testing Methods in Detail
Primary verification uses HPLC with UV detection at 254 nm. Samples dissolve in methanol, then chromatograph on a C18 column with a mobile phase of acetonitrile-phosphate buffer (pH 4.5). Peak area ratios compare to USP clonazepam reference standard, calculating assay percentage. Dissolution testing per USP <711> confirms release rates (e.g., ≥80% in 30 minutes in 0.1N HCl for 0.5 mg tablets).[3][4]
Impurity profiling via HPLC detects degradation products below 0.5% limits, while uniformity of dosage units (USP <905>) checks content variation across 10 tablets (≤15% RSD).[2]
FDA Inspections and Validation
Aurobindo's facilities undergo FDA audits verifying these methods. For clonazepam ANDAs (e.g., 076383 for 0.5 mg tablets), bioequivalence studies include potency assays showing 95-105% recovery. Validation protocols document method precision (RSD <2%), accuracy (±2% bias), and robustness per ICH Q2(R1).[5][6]
Recalls or Issues with Strength Verification
Aurobindo issued a 2021 recall (Lot E41A001, 2 mg clonazepam) for subpotent tablets (87-94% labeled amount), traced to HPLC-detected assay failure during stability testing. Root cause was equipment calibration drift, resolved with enhanced preventive maintenance.[7]
How This Compares to Other Generics Makers
Like Teva or Accord, Aurobindo follows identical USP/FDA protocols, but scales production at multiple sites (e.g., India, USA). Patient complaints on potency (e.g., via FDA MedWatch) occur across brands at ~1-2% rate, often due to storage rather than manufacturing.[8]
Sources
[1]: USP Clonazepam Monograph
[2]: FDA cGMP Guidance
[3]: Aurobindo ANDA Label, 0.5 mg Clonazepam
[4]: USP <711> Dissolution
[5]: FDA Inspection Report, Aurobindo Unit-VI
[6]: ICH Q2(R1) Validation
[7]: FDA Recall Notice E41A001
[8]: FDA Adverse Event Reporting System